The impact of depressive symptoms in early Parkinson disease.
Identifieur interne : 000158 ( PubMed/Corpus ); précédent : 000157; suivant : 000159The impact of depressive symptoms in early Parkinson disease.
Auteurs : B. Ravina ; R. Camicioli ; P Como ; L. Marsh ; J. Jankovic ; D. Weintraub ; J. ElmSource :
- Neurology ; 2007.
English descriptors
- KwdEn :
- Activities of Daily Living, Aged, Antidepressive Agents (therapeutic use), Antiparkinson Agents (adverse effects), Clinical Trials, Phase II as Topic (statistics & numerical data), Cohort Studies, Comorbidity, Depressive Disorder (diagnosis), Depressive Disorder (drug therapy), Depressive Disorder (epidemiology), Disability Evaluation, Double-Blind Method, Early Diagnosis, Female, Humans, Male, Mass Screening, Middle Aged, Motor Activity (drug effects), Motor Activity (physiology), Neuropsychological Tests, Parkinson Disease (drug therapy), Parkinson Disease (epidemiology), Parkinson Disease (physiopathology), Parkinson Disease (psychology), Predictive Value of Tests, Prevalence, Proportional Hazards Models, Randomized Controlled Trials as Topic (statistics & numerical data), Reproducibility of Results.
- MESH :
- chemical , adverse effects : Antiparkinson Agents.
- chemical , therapeutic use : Antidepressive Agents.
- diagnosis : Depressive Disorder.
- drug effects : Motor Activity.
- drug therapy : Depressive Disorder, Parkinson Disease.
- epidemiology : Depressive Disorder, Parkinson Disease.
- physiology : Motor Activity.
- physiopathology : Parkinson Disease.
- psychology : Parkinson Disease.
- statistics & numerical data : Clinical Trials, Phase II as Topic, Randomized Controlled Trials as Topic.
- Activities of Daily Living, Aged, Cohort Studies, Comorbidity, Disability Evaluation, Double-Blind Method, Early Diagnosis, Female, Humans, Male, Mass Screening, Middle Aged, Neuropsychological Tests, Predictive Value of Tests, Prevalence, Proportional Hazards Models, Reproducibility of Results.
Abstract
Depressive disorders may affect up to 50% of patients with Parkinson disease (PD) and are associated with increased disability and reduced quality of life. No previous study has systematically examined the impact of depressive symptoms in early, untreated PD.
DOI: 10.1212/01.wnl.0000268695.63392.10
PubMed: 17581943
Links to Exploration step
pubmed:17581943Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The impact of depressive symptoms in early Parkinson disease.</title><author><name sortKey="Ravina, B" sort="Ravina, B" uniqKey="Ravina B" first="B" last="Ravina">B. Ravina</name><affiliation><nlm:affiliation>Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA. Bernard.ravina@ctcc.rochester.edu</nlm:affiliation></affiliation></author><author><name sortKey="Camicioli, R" sort="Camicioli, R" uniqKey="Camicioli R" first="R" last="Camicioli">R. Camicioli</name></author><author><name sortKey="Como, P G" sort="Como, P G" uniqKey="Como P" first="P" last="Como">P Como</name></author><author><name sortKey="Marsh, L" sort="Marsh, L" uniqKey="Marsh L" first="L" last="Marsh">L. Marsh</name></author><author><name sortKey="Jankovic, J" sort="Jankovic, J" uniqKey="Jankovic J" first="J" last="Jankovic">J. Jankovic</name></author><author><name sortKey="Weintraub, D" sort="Weintraub, D" uniqKey="Weintraub D" first="D" last="Weintraub">D. Weintraub</name></author><author><name sortKey="Elm, J" sort="Elm, J" uniqKey="Elm J" first="J" last="Elm">J. Elm</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2007">2007</date><idno type="doi">10.1212/01.wnl.0000268695.63392.10</idno><idno type="RBID">pubmed:17581943</idno><idno type="pmid">17581943</idno><idno type="wicri:Area/PubMed/Corpus">000158</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">The impact of depressive symptoms in early Parkinson disease.</title><author><name sortKey="Ravina, B" sort="Ravina, B" uniqKey="Ravina B" first="B" last="Ravina">B. Ravina</name><affiliation><nlm:affiliation>Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA. Bernard.ravina@ctcc.rochester.edu</nlm:affiliation></affiliation></author><author><name sortKey="Camicioli, R" sort="Camicioli, R" uniqKey="Camicioli R" first="R" last="Camicioli">R. Camicioli</name></author><author><name sortKey="Como, P G" sort="Como, P G" uniqKey="Como P" first="P" last="Como">P Como</name></author><author><name sortKey="Marsh, L" sort="Marsh, L" uniqKey="Marsh L" first="L" last="Marsh">L. Marsh</name></author><author><name sortKey="Jankovic, J" sort="Jankovic, J" uniqKey="Jankovic J" first="J" last="Jankovic">J. Jankovic</name></author><author><name sortKey="Weintraub, D" sort="Weintraub, D" uniqKey="Weintraub D" first="D" last="Weintraub">D. Weintraub</name></author><author><name sortKey="Elm, J" sort="Elm, J" uniqKey="Elm J" first="J" last="Elm">J. Elm</name></author></analytic><series><title level="j">Neurology</title><idno type="e-ISSN">1526-632X</idno><imprint><date when="2007" type="published">2007</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Activities of Daily Living</term><term>Aged</term><term>Antidepressive Agents (therapeutic use)</term><term>Antiparkinson Agents (adverse effects)</term><term>Clinical Trials, Phase II as Topic (statistics & numerical data)</term><term>Cohort Studies</term><term>Comorbidity</term><term>Depressive Disorder (diagnosis)</term><term>Depressive Disorder (drug therapy)</term><term>Depressive Disorder (epidemiology)</term><term>Disability Evaluation</term><term>Double-Blind Method</term><term>Early Diagnosis</term><term>Female</term><term>Humans</term><term>Male</term><term>Mass Screening</term><term>Middle Aged</term><term>Motor Activity (drug effects)</term><term>Motor Activity (physiology)</term><term>Neuropsychological Tests</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (epidemiology)</term><term>Parkinson Disease (physiopathology)</term><term>Parkinson Disease (psychology)</term><term>Predictive Value of Tests</term><term>Prevalence</term><term>Proportional Hazards Models</term><term>Randomized Controlled Trials as Topic (statistics & numerical data)</term><term>Reproducibility of Results</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antidepressive Agents</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Depressive Disorder</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Motor Activity</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Depressive Disorder</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Depressive Disorder</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Motor Activity</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Clinical Trials, Phase II as Topic</term><term>Randomized Controlled Trials as Topic</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Activities of Daily Living</term><term>Aged</term><term>Cohort Studies</term><term>Comorbidity</term><term>Disability Evaluation</term><term>Double-Blind Method</term><term>Early Diagnosis</term><term>Female</term><term>Humans</term><term>Male</term><term>Mass Screening</term><term>Middle Aged</term><term>Neuropsychological Tests</term><term>Predictive Value of Tests</term><term>Prevalence</term><term>Proportional Hazards Models</term><term>Reproducibility of Results</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Depressive disorders may affect up to 50% of patients with Parkinson disease (PD) and are associated with increased disability and reduced quality of life. No previous study has systematically examined the impact of depressive symptoms in early, untreated PD.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">17581943</PMID><DateCreated><Year>2007</Year><Month>07</Month><Day>24</Day></DateCreated><DateCompleted><Year>2007</Year><Month>08</Month><Day>20</Day></DateCompleted><DateRevised><Year>2014</Year><Month>09</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>69</Volume><Issue>4</Issue><PubDate><Year>2007</Year><Month>Jul</Month><Day>24</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>The impact of depressive symptoms in early Parkinson disease.</ArticleTitle><Pagination><MedlinePgn>342-7</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Depressive disorders may affect up to 50% of patients with Parkinson disease (PD) and are associated with increased disability and reduced quality of life. No previous study has systematically examined the impact of depressive symptoms in early, untreated PD.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We administered the 15-item Geriatric Depression Scale (GDS-15) as part of two NIH-sponsored phase II clinical trials in PD, enrolling 413 early, untreated PD subjects. We used linear mixed models to examine the relationship of depressive symptoms, measured by the GDS-15, with motor function and activities of daily living (ADLs), as measured by the Unified PD Rating Scale (UPDRS). A time-dependent Cox model was used to examine the effect of demographic and clinical outcome measures as predictors of investigator-determined time to need for symptomatic therapy for PD.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 114 (27.6%) subjects screened positive for depression during the average 14.6 months of follow-up. Forty percent of these subjects were neither treated with antidepressants nor referred for further psychiatric evaluation. Depression, as assessed by the GDS-15, was a significant predictor of more impairment in ADLs (p < 0.0001) and increased need for symptomatic therapy of PD (hazard ratio = 1.86; 95% CI 1.29, 2.68).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Clinically important depressive symptoms are common in early Parkinson disease (PD), but are often not treated. Depressive symptoms are an important contributor to disability and the decision to start symptomatic therapy for motor-related impairment in early PD, highlighting the broad importance of identifying and treating depression in this population.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ravina</LastName><ForeName>B</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA. Bernard.ravina@ctcc.rochester.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Camicioli</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Como</LastName><ForeName>P G</ForeName><Initials>PG</Initials></Author><Author ValidYN="Y"><LastName>Marsh</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Jankovic</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Weintraub</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Elm</LastName><ForeName>J</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K23 MH067894</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 MH067894-04</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01NS043127</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01NS043128</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>06</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Biol Psychiatry. 2003 Aug 1;54(3):363-75</RefSource><PMID Version="1">12893111</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Parkinsonism Relat Disord. 2002 Jan;8(3):193-7</RefSource><PMID Version="1">12039431</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arch Clin Neuropsychol. 2003 Jul;18(5):509-20</RefSource><PMID Version="1">14591446</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Am Geriatr Soc. 2004 May;52(5):784-8</RefSource><PMID Version="1">15086662</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neuropsychiatry Clin Neurosci. 2004 Summer;16(3):315-9</RefSource><PMID Version="1">15377738</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arch Neurol. 1988 May;45(5):497-501</RefSource><PMID Version="1">3358699</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Psychol Med. 1988 Feb;18(1):49-55</RefSource><PMID Version="1">3363044</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neuropathol Exp Neurol. 1991 Nov;50(6):743-55</RefSource><PMID Version="1">1748881</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arch Neurol. 1992 Mar;49(3):305-7</RefSource><PMID Version="1">1536634</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurol Neurosurg Psychiatry. 1992 May;55(5):377-82</RefSource><PMID Version="1">1602311</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arch Neurol. 1996 Feb;53(2):175-9</RefSource><PMID Version="1">8639068</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neural Transm (Vienna). 1996;103(3):349-54</RefSource><PMID Version="1">8739846</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neuropsychiatry Clin Neurosci. 1996 Winter;8(1):20-5</RefSource><PMID Version="1">8845697</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 1998 Jan;13(1):29-33</RefSource><PMID Version="1">9452322</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Med Care. 2004 Dec;42(12):1153-7</RefSource><PMID Version="1">15550794</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Gen Hosp Psychiatry. 2006 Jan-Feb;28(1):59-64</RefSource><PMID Version="1">16377367</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Geriatr Psychiatry. 2006 Feb;14(2):169-75</RefSource><PMID Version="1">16473982</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2006 Feb;21(2):148-58</RefSource><PMID Version="1">16211591</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 2006 Mar 14;66(5):664-71</RefSource><PMID Version="1">16481597</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Intern Med. 2006 Apr 4;144(7):496-504</RefSource><PMID Version="1">16585663</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Neurol Neurosurg. 2006 Jul;108(5):465-9</RefSource><PMID Version="1">16150537</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Psychiatry. 2006 Sep;163(9):1493-501</RefSource><PMID Version="1">16946172</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neuropsychiatry Clin Neurosci. 2006 Summer;18(3):377-83</RefSource><PMID Version="1">16963587</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Health Psychol. 2006 Nov;25(6):675-7</RefSource><PMID Version="1">17100495</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 2007 Jan 2;68(1):20-8</RefSource><PMID Version="1">17200487</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2007 Jul 15;22(9):1331-5</RefSource><PMID Version="1">17546674</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Geriatr Psychiatry Neurol. 2003 Sep;16(3):178-83</RefSource><PMID Version="1">12967062</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurol Neurosurg Psychiatry. 2000 Sep;69(3):308-12</RefSource><PMID Version="1">10945804</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Am Geriatr Soc. 2000 Aug;48(8):938-42</RefSource><PMID Version="1">10968298</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Neurology. 2007 Jul 24;69(4):E2-3</RefSource><PMID Version="1">17646622</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000203">Activities of Daily Living</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000928">Antidepressive Agents</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000978">Antiparkinson Agents</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D017322">Clinical Trials, Phase II as Topic</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000706">statistics & numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015331">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015897">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003866">Depressive Disorder</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000453">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004185">Disability Evaluation</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004311">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D042241">Early Diagnosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008403">Mass Screening</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009043">Motor Activity</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName><QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009483">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000453">epidemiology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000523">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011237">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015995">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016016">Proportional Hazards Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016032">Randomized Controlled Trials as Topic</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000706">statistics & numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015203">Reproducibility of Results</DescriptorName></MeshHeading></MeshHeadingList><OtherID Source="NLM">NIHMS29015</OtherID><OtherID Source="NLM">PMC2031220</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="aheadofprint"><Year>2007</Year><Month>6</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>6</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>8</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>6</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pii">01.wnl.0000268695.63392.10</ArticleId><ArticleId IdType="doi">10.1212/01.wnl.0000268695.63392.10</ArticleId><ArticleId IdType="pubmed">17581943</ArticleId><ArticleId IdType="pmc">PMC2031220</ArticleId><ArticleId IdType="mid">NIHMS29015</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/JankovicV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000158 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000158 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= JankovicV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:17581943
|texte= The impact of depressive symptoms in early Parkinson disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:17581943" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a JankovicV1
| This area was generated with Dilib version V0.6.19. |  |